================================================================================
WHO 2022 vs ICC 2022 DIFFERENTIAL DIAGNOSIS ANALYSIS REPORT
================================================================================

📊 SUMMARY
----------------------------------------
Total tests run: 204
Equivalent results: 121 (59.3%)
Different results: 83 (40.7%)

Differences by significance:
  High impact: 35
  Medium impact: 48
  Low impact: 0

🚨 CRITICAL: DISEASE TYPE DISAGREEMENTS (AML vs MDS)
------------------------------------------------------------
Total AML vs MDS disagreements: 73
Disease disagreement rate: 35.8%

WHO classifies as MDS, ICC as AML: 72 cases
  (ICC allows lower blast thresholds for AML with defining mutations)
WHO classifies as AML, ICC as MDS: 1 cases
  (Different handling of dysplastic features vs blast percentage)

Disease disagreements by blast percentage:
  <10%: 1 cases
  10-14%: 22 cases
  15-19%: 50 cases

Examples of AML vs MDS disagreements:
  1. Test test_000004: 9% blasts
     WHO: AML - AML with NPM1 mutation (WHO 2022)
     ICC: MDS - MDS with excess blasts (ICC 2022)
  2. Test test_000005: 10% blasts
     WHO: MDS - MDS with increased blasts 2 (WHO 2022)
     ICC: AML - MDS/AML, NOS (ICC 2022)
  3. Test test_000006: 10% blasts
     WHO: MDS - MDS with increased blasts 2 (WHO 2022)
     ICC: AML - AML with in-frame bZIP mutated CEBPA (ICC 2022)
  4. Test test_000007: 10% blasts
     WHO: MDS - MDS with increased blasts 2 (WHO 2022)
     ICC: AML - AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)
  5. Test test_000009: 15% blasts
     WHO: MDS - MDS with increased blasts 2 (WHO 2022)
     ICC: AML - MDS/AML, NOS (ICC 2022)

🎯 DIFFERENCES BY TEST FOCUS AREA
----------------------------------------
  blast_thresholds: 12 differences
  therapy_qualifiers: 1 differences
  tp53_terminology: 6 differences
  mds_blast_ranges: 18 differences
  erythroid_handling: 8 differences
  combination_scenarios: 2 differences
  realistic_clinical_scenarios: 2 differences
  age_dependent_differences: 10 differences
  complex_cytogenetics: 2 differences
  comutation_patterns: 4 differences
  therapy_evolution: 2 differences
  aml_vs_mds_borderline: 11 differences
  disease_type_disagreement: 5 differences

⚠️  HIGH IMPACT DIFFERENCES
----------------------------------------
1. Test test_000004 (blast_thresholds)
   WHO: AML with NPM1 mutation (WHO 2022)
   ICC: MDS with excess blasts (ICC 2022)
   Input: blasts=9%
   🚨 DISEASE TYPE DISAGREEMENT: WHO=AML, ICC=MDS

2. Test test_000006 (blast_thresholds)
   WHO: MDS with increased blasts 2 (WHO 2022)
   ICC: AML with in-frame bZIP mutated CEBPA (ICC 2022)
   Input: blasts=10%
   🚨 DISEASE TYPE DISAGREEMENT: WHO=MDS, ICC=AML

3. Test test_000007 (blast_thresholds)
   WHO: MDS with increased blasts 2 (WHO 2022)
   ICC: AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)
   Input: blasts=10%
   🚨 DISEASE TYPE DISAGREEMENT: WHO=MDS, ICC=AML

4. Test test_000010 (blast_thresholds)
   WHO: MDS with increased blasts 2 (WHO 2022)
   ICC: AML with in-frame bZIP mutated CEBPA (ICC 2022)
   Input: blasts=15%
   🚨 DISEASE TYPE DISAGREEMENT: WHO=MDS, ICC=AML

5. Test test_000011 (blast_thresholds)
   WHO: MDS with increased blasts 2 (WHO 2022)
   ICC: AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)
   Input: blasts=15%
   🚨 DISEASE TYPE DISAGREEMENT: WHO=MDS, ICC=AML

6. Test test_000014 (blast_thresholds)
   WHO: MDS with increased blasts 2 (WHO 2022)
   ICC: AML with in-frame bZIP mutated CEBPA (ICC 2022)
   Input: blasts=19%
   🚨 DISEASE TYPE DISAGREEMENT: WHO=MDS, ICC=AML

7. Test test_000015 (blast_thresholds)
   WHO: MDS with increased blasts 2 (WHO 2022)
   ICC: AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)
   Input: blasts=19%
   🚨 DISEASE TYPE DISAGREEMENT: WHO=MDS, ICC=AML

8. Test test_000017 (blast_thresholds)
   WHO: AML with CEBPA mutation (WHO 2022)
   ICC: AML, NOS (ICC 2022)
   Input: blasts=20%

9. Test test_000021 (blast_thresholds)
   WHO: AML with CEBPA mutation (WHO 2022)
   ICC: AML, NOS (ICC 2022)
   Input: blasts=25%

10. Test test_000027 (therapy_qualifiers)
   WHO: Acute myeloid leukaemia, unknown differentiation (WHO 2022)
   ICC: AML, NOS, therapy related (ICC 2022)
   Input: blasts=25.0%

11. Test test_000072 (tp53_terminology)
   WHO: AML, myelodysplasia related (WHO 2022)
   ICC: AML with mutated TP53 (ICC 2022)
   Input: blasts=20%

12. Test test_000074 (tp53_terminology)
   WHO: AML, myelodysplasia related (WHO 2022)
   ICC: AML with mutated TP53 (ICC 2022)
   Input: blasts=25%

13. Test test_000103 (mds_blast_ranges)
   WHO: MDS, fibrotic (WHO 2022)
   ICC: MDS/AML, NOS (ICC 2022)
   Input: blasts=10%
   🚨 DISEASE TYPE DISAGREEMENT: WHO=MDS, ICC=AML

14. Test test_000109 (mds_blast_ranges)
   WHO: MDS, fibrotic (WHO 2022)
   ICC: MDS/AML, NOS (ICC 2022)
   Input: blasts=15%
   🚨 DISEASE TYPE DISAGREEMENT: WHO=MDS, ICC=AML

15. Test test_000115 (mds_blast_ranges)
   WHO: MDS, fibrotic (WHO 2022)
   ICC: MDS/AML, NOS (ICC 2022)
   Input: blasts=19%
   🚨 DISEASE TYPE DISAGREEMENT: WHO=MDS, ICC=AML

16. Test test_000123 (erythroid_handling)
   WHO: Acute Erythroid leukaemia (WHO 2022)
   ICC: MDS/AML, NOS (ICC 2022)
   Input: blasts=15%

17. Test test_000124 (erythroid_handling)
   WHO: Acute Erythroid leukaemia (WHO 2022)
   ICC: AML, NOS (ICC 2022)
   Input: blasts=20%

18. Test test_000125 (erythroid_handling)
   WHO: Acute Erythroid leukaemia (WHO 2022)
   ICC: AML, NOS (ICC 2022)
   Input: blasts=25%

19. Test test_000126 (erythroid_handling)
   WHO: Acute Erythroid leukaemia (WHO 2022)
   ICC: AML, NOS (ICC 2022)
   Input: blasts=30%

20. Test test_000127 (erythroid_handling)
   WHO: Acute Erythroid leukaemia (WHO 2022)
   ICC: MDS/AML, NOS (ICC 2022)
   Input: blasts=15%

21. Test test_000128 (erythroid_handling)
   WHO: Acute Erythroid leukaemia (WHO 2022)
   ICC: AML, NOS (ICC 2022)
   Input: blasts=20%

22. Test test_000129 (erythroid_handling)
   WHO: Acute Erythroid leukaemia (WHO 2022)
   ICC: AML, NOS (ICC 2022)
   Input: blasts=25%

23. Test test_000130 (erythroid_handling)
   WHO: Acute Erythroid leukaemia (WHO 2022)
   ICC: AML, NOS (ICC 2022)
   Input: blasts=30%

24. Test test_000147 (realistic_clinical_scenarios)
   WHO: MDS, fibrotic (WHO 2022)
   ICC: MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)
   Input: blasts=15%
   🚨 DISEASE TYPE DISAGREEMENT: WHO=MDS, ICC=AML

25. Test test_000150 (age_dependent_differences)
   WHO: Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation (WHO 2022)
   ICC: AML, NOS, in the setting of germline RUNX1 mutation (ICC 2022)
   Input: blasts=25%

26. Test test_000151 (age_dependent_differences)
   WHO: Acute myeloid leukaemia, unknown differentiation, associated with germline DDX41 mutation (WHO 2022)
   ICC: AML, NOS, in the setting of germline DDX41 mutation (ICC 2022)
   Input: blasts=25%

27. Test test_000154 (age_dependent_differences)
   WHO: Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation (WHO 2022)
   ICC: AML, NOS, in the setting of germline RUNX1 mutation (ICC 2022)
   Input: blasts=20%

28. Test test_000155 (age_dependent_differences)
   WHO: Acute myeloid leukaemia, unknown differentiation, associated with germline DDX41 mutation (WHO 2022)
   ICC: AML, NOS, in the setting of germline DDX41 mutation (ICC 2022)
   Input: blasts=20%

29. Test test_000156 (age_dependent_differences)
   WHO: MDS with increased blasts 2 (WHO 2022)
   ICC: AML with in-frame bZIP mutated CEBPA (ICC 2022)
   Input: blasts=18%
   🚨 DISEASE TYPE DISAGREEMENT: WHO=MDS, ICC=AML

30. Test test_000158 (age_dependent_differences)
   WHO: MDS with increased blasts 2, associated with germline RUNX1 mutation (WHO 2022)
   ICC: MDS/AML, NOS, in the setting of germline RUNX1 mutation (ICC 2022)
   Input: blasts=18%
   🚨 DISEASE TYPE DISAGREEMENT: WHO=MDS, ICC=AML

31. Test test_000160 (age_dependent_differences)
   WHO: MDS with increased blasts 2 (WHO 2022)
   ICC: AML with in-frame bZIP mutated CEBPA (ICC 2022)
   Input: blasts=15%
   🚨 DISEASE TYPE DISAGREEMENT: WHO=MDS, ICC=AML

32. Test test_000162 (age_dependent_differences)
   WHO: MDS with increased blasts 2, associated with germline RUNX1 mutation (WHO 2022)
   ICC: MDS/AML, NOS, in the setting of germline RUNX1 mutation (ICC 2022)
   Input: blasts=15%
   🚨 DISEASE TYPE DISAGREEMENT: WHO=MDS, ICC=AML

33. Test test_000164 (complex_cytogenetics)
   WHO: AML, myelodysplasia related (WHO 2022)
   ICC: AML with mutated TP53 (ICC 2022)
   Input: blasts=22%

34. Test test_000173 (comutation_patterns)
   WHO: AML, myelodysplasia related (WHO 2022)
   ICC: AML with mutated TP53 (ICC 2022)
   Input: blasts=35%

35. Test test_000201 (disease_type_disagreement)
   WHO: MDS with increased blasts 2 (WHO 2022)
   ICC: AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)
   Input: blasts=12%
   🚨 DISEASE TYPE DISAGREEMENT: WHO=MDS, ICC=AML


Blast threshold differences:
  <10%: 1 cases
  10-14%: 18 cases
  15-19%: 47 cases
  20-24%: 7 cases
  25-29%: 7 cases
  ≥30%: 3 cases

Mutation patterns:
  NPM1:
    count: 1 cases
    aml_defining: True cases
  CEBPA:
    count: 8 cases
    aml_defining: True cases
  bZIP:
    count: 5 cases
    aml_defining: True cases
  BCR::ABL1:
    count: 4 cases
    aml_defining: True cases
  SF3B1:
    count: 5 cases
    mds_related: True cases
  ASXL1:
    count: 7 cases
    mds_related: True cases
  RUNX1:
    count: 1 cases
    mds_related: True cases
  SRSF2:
    count: 3 cases
    mds_related: True cases
  TET2:
    count: 4 cases
    mds_related: True cases
  EZH2:
    count: 1 cases
    mds_related: True cases
  CEBPA_bZIP:
    count: 2 cases
    aml_defining: True cases
  NPM1_mutation:
    count: 3 cases
    aml_defining: True cases
  RUNX1_RUNX1T1:
    count: 1 cases
    aml_defining: True cases
  CBFB_MYH11:
    count: 1 cases
    aml_defining: True cases
  U2AF1:
    count: 1 cases
    mds_related: True cases
  DNMT3A:
    count: 1 cases
    mds_related: True cases
  FLT3_ITD:
    count: 1 cases
    aml_defining: True cases
  KMT2A_rearranged:
    count: 1 cases
    aml_defining: True cases
  TP53:
    count: 1 cases
    mds_related: True cases


================================================================================